GlassScriptPhysician profile
Charles W Phillips
NPI 1730101155
$1,046.96
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $177 · 2021: $75.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $286.81 | 2019-2021 | |
| Medtronic Vascular, INC. | $196.29 | 2019 | |
| Edwards Lifesciences Corporation | $129.44 | 2019 | |
| Asahi Intecc USA, INC. | $109.92 | 2019 | |
| Atricure, INC. | $73.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $57.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $31.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.94 | 2019 | |
| Abbvie INC. | $22.30 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.33 | 2019 | |
| Genentech USA, INC. | $17.51 | 2020 | |
| Amgen INC. | $17.44 | 2019 | |
| Abbott Laboratories | $17.44 | 2021 | |
| Tactile Systems Technology INC | $15.01 | 2019 | |
| Pfizer INC. | $14.79 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.